<DOC>
	<DOCNO>NCT00092807</DOCNO>
	<brief_summary>This extension study patient unusually high absorption non-cholesterol sterol , result heart-related disease . This study evaluate long term safety ability lower cholesterol level investigational drug .</brief_summary>
	<brief_title>Sitosterolemia Extension Study ( 0653-003 ) ( COMPLETED )</brief_title>
	<detailed_description>The duration treatment 52 week .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Lipid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients elevate sitosterol level take current medication Patient condition , opinion investigator , might pose risk patient , interfere participation study , meet additional criterion require study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Homozygous Sitosterolemia</keyword>
</DOC>